IP Library Granted Patent US 9,125,948
Granted Patent B2
US 9,125,948 · App. 12/965,221 · Granted Sep 8, 2015

Ion exchange resin treated to control swelling

Inventors: Harlan Hall (Oregon, WI); J. Scott Madsen (Cottage Grove, WI)
Assignee: Coating Place, Inc.
A61K47/48184A61K9/0095A61K9/146A61K31/137A61K31/192A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,125,948
App. No.
12/965,221
Granted
Sep 8, 2015
Kind
B2
Abstract

The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the solution to load more drugs onto the drug-loaded resin particle from the solution.

Claims (30)

1. A product obtained by:

a) loading in a solution one or more drugs onto one or more ion exchange resin particles to form drug-loaded resin particle(s);

b) separating the drug-loaded resin particle(s) from the solution and recovering filtrate containing unbound drug; and

c) coating the recovered filtrate from step (b) back onto the drug-loaded resin particle(s) using a fluid bed coating equipment;

such that in the product, one or more drugs are ionically bound to ion exchange resin particles after loading step a), and the remaining drugs are directly coated onto the surface of the ion exchange resin particles by coating step c) through a non-ionic interaction.

2. The product of claim 1 , further comprising the step of drying the drug-loaded resin particle(s) then coating the recovered filtrate back onto the drug-loaded resin particle.

3. The product of claim 1 , wherein the step of separating is selected from the group consisting of filtration, extraction, distillation, precipitation, amalgamation or a combination or series thereof.

4. The product of claim 2 , wherein the drying is accomplished by the use of an oven dryer, flash dryer, spray dryer, a fluid bed dryer or a combination thereof.

5. The product of claim 1 , wherein the step of loading lasts between about 0.1 and 12 hours.

6. The product of claim 1 , further comprising the step of loading one or more sugar alcohols to the drug-loaded resin particle(s).

7. The product of claim 6 , wherein the one or more sugar alcohols is selected from the group consisting of mannitol, sorbitol, xylitol, maltitol, lactitol, 1,3-dihydroxypropane, inositol glucose, sucrose and mixtures or combinations thereof.

8. The product of claim 1 , wherein the ion exchange resin particles comprise sulfonic acid cationic exchange resin particles.

9. The product of claim 1 , wherein the ionic exchange resin comprises polymers of dipropylene glycol diallyl ether, polyglycol diallyl ether, triethylene glycol divinyl ether, hydroquinone diallyl ether, tetraallyloxyethanoyl, vinyl ether, vinyl acetate, vinyl butylbenzoate, crotonic acid, polyfunctional alcohol, tetraethylene glycol diacrylate, triallylamine, trimethylolpropane diallyl ether, methylenebisacrylamide, divinylbenzene, phthalic, sulphonphthalic acid, ethylene glycol, polymethyl siloxane α,γ-hydroxypropyl or combination thereof.

10. The product of claim 1 , wherein the loading solution comprises a second drug selected from narcotic analgesics, sympathomimetics, antitussives, analgesics antiemetics, anticholinergics, muscle relaxants, bronchodilators, antibiotics, antidepressants, antiasthmatics, antineoplastics, antiepileptics, cardiovascular agents, mixtures and combinations thereof.

11. The product of claim 1 , further comprising the step of coating the ion exchange resin particles with a water-permeable diffusion barrier.

12. The product of claim 1 , further comprising the step of drying the drug-loaded resin particle(s) after the separation of the drug-loaded resin particle(s) from the solution.

13. The product of claim 1 , wherein the one or more drugs is selected from the group consisting of narcotic analgesics, sympathomimetics, antitussives, analgesics antiemetics, anticholinergics, muscle relaxants, bronchodilators, antibiotics, antidepressants, antiasthmatics, antineoplastics, antiepileptics, cardiovascular agents, mixtures and combinations thereof.

14. The product of claim 1 , wherein the one or more drugs is selected from the group consisting of codeine, dihydrocodeine, hydromorphone, morphine, pentazocine, propoxyphene, norephedrine, pseudoephedrine, dextromethorphan, aspirin, tramadol, metoclopramide, atropine, ipratropium bromide, scopolamine, cyclobenzaprine, papaverine, salbutamol, terbutaline and theophylline, amoxycillin, ampicillin, azlocillin, bacampicillin, cefamandole, cefonicid, cefotaxime, cefotetan, cefoxitin, ceftriaxone, mezlocillin, piperacillin, bupropion, nomifensine, nortriptyline, cromolyn, tamoxifen, valproic acid and phenvtoin, propranolol mixtures and combinations thereof.

15. A product obtained by:

a) loading in a solution one or more drugs onto one or more ion exchange resin particles to form drug-loaded resin particle(s);

b) separating the drug-loaded resin particle(s) from the solution and recovering filtrate containing unbound drug;

c) coating the recovered filtrate from step (b) back onto the drug-loaded resin particle(s) using a fluid bed coating equipment;

d) coating the ion exchange resin particles prepared in step c) with a water-permeable diffusion barrier; and

e) suspending the drug-loaded resin particle(s) in a liquid;

such that in the product, one or more drugs are ionically bound to ion exchange resin particles after loading step a), and the remaining drugs are directly coated onto the surface of the ion exchange resin particles by coating step c) through a non-ionic interaction.

16. The product of claim 15 , wherein the liquid is a syrup.

17. The product of claim 1 , wherein the product is a controlled release composition.

18. The product of claim 16 , wherein the drug is dextromethorphan or a pharmaceutically acceptable salt thereof.

19. The product of claim 16 , wherein the drug is codeine or a pharmaceutically acceptable salt thereof.

20. The product of claim 16 , wherein the drug is hydrocodone or a pharmaceutically acceptable salt thereof.

Assignments (3)
CHANGE OF NAME Recorded Dec 29, 2025
From: COATING PLACE, INCORPORATED
To: COATING PLACE, LLC
Reel/Frame 074091/0361 →
SECURITY INTEREST Recorded Dec 23, 2025
From: COATING PLACE, LLC
To: APOGEM CAPITAL LLC, AS AGENT
Reel/Frame 073303/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2010
From: HALL, HARLAN; MADSEN, J. SCOTT
To: COATING PLACE, INC.
Reel/Frame 025529/0901 →
Continuity (3)
Continuation 11674921 · Feb 14, 2007
Continuation In Part 11225834 · Sep 13, 2005
Related Publication 20110081419A1 · Apr 7, 2011